Burden of serious harms from diagnostic error in the USA


ABSTRACT
Background Diagnostic errors cause substantial preventable harms worldwide, but rigorous estimates for total burden are lacking. We previously estimated diagnostic error and serious harm rates for key dangerous diseases in major disease categories and validated plausible ranges using clinical experts.

Objective We sought to estimate the annual US burden of serious misdiagnosis-related harms (permanent morbidity, mortality) by combining prior results with rigorous estimates of disease incidence.

Methods Cross-sectional analysis of US-based nationally representative observational data. We estimated annual incident vascular events and infections from 21.5 million (M) sampled US hospital discharges (2012–2014). Annual new cancers were taken from US-based registries (2014). Years were selected for coding consistency with prior literature. Disease-specific incidences for 15 major vascular events, infections and cancers (‘Big Three’ categories) were multiplied by literature-based rates to derive diagnostic errors and serious harms. We calculated uncertainty estimates using Monte Carlo simulations. Validity checks included sensitivity analyses and comparison with prior published estimates.

Results Annual US incidence was 6.0 M vascular events, 6.2 M infections and 1.5 M cancers. Per ‘Big Three’ dangerous disease case, weighted mean error and serious harm rates were 1.1% and 4.4%, respectively. Extrapolating to all diseases (including non-‘Big Three’ dangerous disease categories), we estimated total serious harms annually in the USA to be 795,000 (plausible range 589,000–1,023,000). Sensitivity analyses using more conservative assumptions estimated 549,000 serious harms. Results were compatible with setting-specific serious harm estimates from inpatient, emergency department and ambulatory care. The 15 dangerous diseases accounted for 50.7% of total serious harms and the top 5 (stroke, sepsis, pneumonia, venous thromboembolism and lung cancer) accounted for 38.7%.

Conclusion An estimated 795,000 Americans become permanently disabled or die annually across care settings because dangerous diseases are misdiagnosed. Just 15 diseases account for about half of all serious harms, so the problem may be more tractable than previously imagined.

INTRODUCTION
Diagnostic error is a major source of preventable harms worldwide across clinical settings,1–6 but epidemiologically valid estimates of overall misdiagnosis-related morbidity and mortality are lacking. The US National Academy of Medicine describes improving diagnosis in healthcare as a ‘moral, professional, and public health imperative’.7 In its 2015 report, the National Academy concluded that ‘most people will experience at least
one diagnostic error in their lifetime, sometimes with devastating consequences’. However, the report also noted that, ‘the available research estimates [are] not adequate to extrapolate a specific estimate or range of the incidence of diagnostic errors in clinical practice today’. This concern is reflected in the wide variation of US estimates for total annual diagnostic errors (12 million (M) to >100 M) and serious misdiagnosis-related harms (40,000 to 4 M).8 No studies have yet used nationally representative datasets to measure aggregate US diagnostic errors or harms.

Given wide variation in prior estimates of total diagnostic errors and harms,8 9 we pursued a novel disease-based approach to constructing a national estimate that would span ambulatory clinic, emergency department and inpatient care. The disease-based approach leveraged three major disease categories—vascular events, infections and cancers (the ‘Big Three’)—found in both malpractice claims and clinical studies of diagnostic error to account for three-quarters of serious harms.9 To estimate the total US burden of medical misdiagnosis, we multiplied national estimates of disease incidence (including those initially misdiagnosed) by the disease-specific proportion of patients with that disease experiencing errors and harms. We did this for 15 key diseases causing the most harms, then extrapolated to the grand total across all diseases. To assess the robustness of our final estimates, we used sensitivity analyses to measure the impact of methodological choices and tested validity via comparison to prior literature and expert review.

METHODS

This was a three-phase research study in which the first two published components8 9 form the basis of the current analysis, which represents the third and final component (online supplemental file 1-A1). The main goal of this three-phase research project was to estimate the total number of serious misdiagnosis-related harms (ie, permanent disability or death) occurring annually in the USA across all care settings (ambulatory clinic, emergency department and inpatient). As reported previously,8 9 each study phase was designed to answer a key question from a specific data source that would support the final estimate: (1) what dangerous diseases account for the majority of serious misdiagnosis-related harms? (using 10 years of data from a large, nationwide malpractice database representing ~30% of all US claims, then comparing the proportion of ‘Big Three’ diseases with that from clinical practice-based (non-claims) studies8; (2) how common are diagnostic errors potentially causing harm among these dangerous diseases? (using estimates of error and harm rates from high-quality clinical studies,8 9 further validated by experts) and, for this final component, (3) what is the overall epidemiological incidence of diagnostic errors and harms among these dangerous diseases? (using nationally representative databases to measure dangerous disease incidence and multiply these by error and harm rates). This final analysis also extrapolates to all (including non-‘Big Three’) diagnostic errors and serious misdiagnosis-related harms by using the previously reported9 attributable fraction of ‘Big Three’ diseases in clinical practice. We constructed our scientific approach such that the final grand total estimates for errors and harms in the USA are based on clinical literature and US population incidence, not malpractice claims. This is because (a) no error or harm rates were taken from claims-based studies, (b) the extrapolation from ‘Big Three’ disease estimates to the grand total were based on the proportion of ‘Big Three’ diseases causing errors and harms from clinical studies (described in ‘Outcome measures’ section) and (c) any impact of having used malpractice claims to construct the original disease list or weights are mathematically unrelated to the grand totals (online supplemental file 1-A2). We summarise key aspects of prior study methods8 9 as needed for readers to follow this final component.

Diagnostic error, misdiagnosis-related harm and harm severity definitions

As reported previously,8 9 we used published definitions for diagnostic error7 and misdiagnosis-related harms.10 In this study, we considered only false negative diagnoses (ie, initially missed or delayed) and associated harms.1 8 Harms from inappropriate use of inappropriate tests,11 12 or from overdiagnosis (ie, overtreatment of correctly diagnosed conditions that, left undiagnosed, would be unlikely to impact patient health)10 13 were not considered. Harm severity was categorised according to a recognised insurance industry standard for measuring severity of injury in malpractice claims.14 15 Serious (high-severity) misdiagnosis-related harms were defined as scale scores 6–9 representing serious permanent morbidity or mortality (box 1).9

Although technically proportions, we use the more common terminology ‘rates’ to describe diagnostic errors and misdiagnosis-related harms for ease of readability. The diagnostic error rate is the proportion of patients with a target disease who were not diagnosed in accurate and timely fashion; the misdiagnosis-related harm rate is the proportion of patients with a target disease who were not diagnosed in accurate and timely fashion and suffered serious harms from the target disease.

Current study design and data sources

This cross-sectional study multiplied literature-based estimates of diagnostic errors and harms (reported previously by our team8 9) by nationally representative epidemiological data on disease incidence (reported here for the first time) to estimate total misdiagnosis-related harms. Multiplying disease incidence by the disease-specific proportion of patients experiencing
Clinical studies we could find. All studies used for these calculations had to have clinical source populations, so no malpractice or autopsy studies were included. In some cases, studies were from countries outside the USA (Australia, Canada, New Zealand, the UK and several European nations). We discarded lower-quality studies when more rigorous studies (eg, systematic reviews, population-based sampling, large sample sizes, rigorous case ascertainment) were available. Error rates for vascular events and infections were predominantly derived from studies in emergency department or inpatient settings, while error rates for cancers were predominantly registry based. Disease-specific misdiagnosis-related harm rates were derived by multiplying high-quality data on disease-agnostic (non-disease-specific) harms per diagnostic error (from well-respected clinical studies) by disease-specific harm-severity weights (from malpractice claims) (online supplemental file 1-A2).

We derived population-based data on disease incidence from public use datasets employing nationally representative sampling or census methods. This represents the number at risk for diagnostic error across all clinical settings. All age groups were included. The annual incidence of specific conditions within the ‘Big Three’ disease categories (ie, vascular events, infections and cancers) was measured using discharge data from two sources: (1) the National Inpatient Sample (NIS) (2012–2014), Healthcare Cost and Utilisation Project (HCUP), Agency for Healthcare Research and Quality16 and (2) North American Association of Central Cancer Registries (NAACCR)17 curated by the American Cancer Society (ACS) (2014). The year 2014 was chosen as the last full year in which national data were coded using the International Classification of Diseases 9th revision, Clinical Modification (ICD-9-CM), prior to the 2015 transition to the International Classification of Diseases 10th revision, Clinical Modification, for coding consistency with the previously published components of the study.4–9

Disease incidence data for vascular events and infections

The conservative assumption was made that incident cases of dangerous (life or limb-threatening) vascular events and infections in the USA would eventually involve a hospitalisation, even if the patient was initially misdiagnosed in an ambulatory care setting. Outpatient (eg, primary care, emergency department) visit diagnoses were not included separately in the disease incidence calculations because they would risk inflating disease incidence estimates through double counting. For example, if ‘myocardial infarction’ cases that were correctly diagnosed in outpatient care (and then later confirmed as an inpatient) had been included in the analysis, the same incident cases would be counted twice. Out-of-hospital deaths from these conditions were not considered, as cause-of-death
listings on death certificates are known to be inaccurate for some conditions (eg, myocardial infarction). 

HCUP NIS data were used to measure US inpatient hospital stays, counting discharge or in-hospital death diagnoses coded in either the principal or first-listed secondary diagnosis positions, as these diagnoses are often of equal, competing weight. We chose this approach for the primary analysis because (1) using second-position codes can increase sensitivity without sacrificing specificity and (2) ‘secondary’ diagnoses are also incident disease cases with the potential to be misdiagnosed, independent from the ‘primary’ disease (eg, a comorbid stroke in a patient with endocarditis might also be missed and this additional missed opportunity could also harm the patient).

Disease-level and ‘Big Three’ category-level code groupings were the same as those used in prior project phases and double-checked for coherence with NIS analysis (online supplemental file 1-A3). These were derived from HCUP’s Clinical Classification Software, which groups ICD-9-CM codes into clinically meaningful categories. We used NIS data (2012–2014) to estimate the annual number of hospital discharges nationwide by disease and category. A 3-year average was chosen to improve stability of incidence measures for rare conditions (eg, spinal abscess). We followed standard procedures for NIS data to derive nationally representative estimates (online supplemental file 1-A4). 

Disease incidence data for cancers

Inpatient hospital stays would not be a good proxy for incident cancer cases, since cancers are treated in outpatient settings and patients are usually only hospitalised for complications. Instead, national incidence counts by cancer site (ie, body location) were obtained from the 2014 ACS report. As stated in the report, counts were based primarily on incidence data collected by the NAACCR, which represents 89% of the US population. ACS also used other unidentified sources to generate their final counts, but, because both NAACCR and ACS treat these registry-based estimates as a census (ie, no sampling-related uncertainty), we did the same. Some ACS categories were grouped to match the prior disease classification from earlier study phases (eg, colon and rectum cancer grouped as ‘colorectal’).

Outcome measures

The main outcome measures were estimates of total annual diagnostic errors (false negatives) and serious misdiagnosis-related harms (permanent morbidity or mortality) in the USA for 2014, across all clinical settings. Outcomes were calculated for the ‘Big Three’ disease categories, including 15 specific diseases (ie, the previously identified top five vascular events, infections and cancers), ‘other’ (non-top five) diseases within each category and corresponding category totals.

In turn, these ‘Big Three’ results were used to calculate a grand total (including non-‘Big Three’ dangerous diseases) using the clinical proportion of diagnostic errors (58.5%) and serious harms (75.8%) attributable to ‘Big Three’ diseases. These proportions derive exclusively from research studies based in clinical practice (ie, not malpractice claims studies) (see prior citation, p. 237). Mathematically, the grand total of diagnostic errors was calculated by dividing the ‘Big Three’ total number of diagnostic errors by 0.585. Similarly, the grand total of serious misdiagnosis-related harms was calculated by dividing the ‘Big Three’ total number of serious misdiagnosis-related harms by 0.758.

Using the proportion of deaths among serious harms across clinical settings (~46.7%), we estimated total deaths (total serious harms × proportion of deaths among serious harms=total deaths). By subtraction, we estimated total disabilities (total serious harms−total deaths=total disabilities).

Uncertainty estimates were calculated using a probabilistic sampling approach based on Monte Carlo simulations (full statistical R V4.2.2 code is provided in online supplemental file 2). In this manuscript, many ranges are denoted ‘probabilistic plausible ranges’ (PPRs), rather than 95% CIs. This is because they rely on some diagnostic error rates (n=5 cancers) that use literature-derived (and expert-validated) plausible ranges (PRs) rather than statistically derived 95% CIs, reflecting uncertainty beyond mere sampling error (online supplemental file 1-A5). We used PRs for the top five cancers because different studies defined diagnostic delays of different lengths—defining shorter delays as errors created an upper PR bound, while defining longer delays as errors created a lower PR bound.

Sensitivity analyses and validity checks

We used five separate approaches to assess the robustness of our final results: (1) sensitivity analyses using different data assumptions (a) one-way analyses to assess the impact of uncertainty in model parameters by using the lower and higher uncertainty bounds rather than the point estimate and (b) the impact of analysing disease incidence for vascular events and infections using only principal NIS diagnoses (online supplemental file 1-B1,B2); (2) assessing the risk of misestimating deaths by undercounting (incident cases resulting in prehospital death) or overcounting (patients admitted more than once in a given year, yet who could only die once) (online supplemental file 1-B3,B4); (3) comparison with independent hospital and autopsy estimates (online supplemental file 1-C1,C2); (4) triangulation of data derived from studies of diagnostic errors and harms across clinical settings (inpatient, emergency department, ambulatory clinics)
(online supplemental file 1-C3) and (5) an iterative process of expert review by 24 clinical domain experts (following the same method used in our prior publication to validate estimates of error and harm rates), which served as a final check on the face validity of our disease-specific incidence and total harm estimates.

Statistical analysis and reporting
We used sample sizes, totals, means, medians, 95% CIs, IQRs and PPRs to describe populations and outcomes, as appropriate. NIS analysis was conducted using the PROC SURVEYMEANS procedure in SAS V9.3 (Cary, North Carolina, USA). All other statistical calculations were performed using R V4.2.2 (Vienna, Austria). This manuscript follows Enhancing the QUAlity and Transparency Of Health Research (STrengthening the Reporting of Observational Studies in Epidemiology) (STROBE) reporting guidelines for observational studies.

Role of the funding source
The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

RESULTS
Quality of data sources for error and harm rates
Error and harm rates were published previously. For 14 of 15 diseases (besides arterial thromboembolism, where we aggregated four retrospective case series), condition-specific diagnostic error rates were derived from high-quality clinical literature. This included clinical studies with strong designs (large prospective clinical trials or studies using population-based sampling or registries) or meta-analyses of high-quality clinical studies. For condition-specific diagnostic error rates, there were 47 source studies (vascular events (n=28), infections (n=10), cancers (n=9)) representing 942,916 patients (median study sample n=397 (IQR 176–1914); median per-disease sample n=2343 (IQR 398–10 351)). For disease-agnostic harm rates, there were five source studies representing 1216 diagnostic errors and 374 serious harms. Each study operationalised definitions slightly differently (eg, nature of diagnostic reference standard), but all definitions for errors/harms were consistent with published definitions described in the ‘Methods’ section.

US population-based incidence of vascular events, infections, and cancers
The total NIS sample from 2012 to 2014 included 21.5M hospitalisations (for all conditions, not just vascular events or infections), representing a weighted national estimate of 107.4M total discharges (mean annual 35.8M). In 2014, the sample was taken from 4411 different hospitals across 45 states (representing ~80% of hospitals and 90% of states in the USA). The mean weighted annual number of incident vascular events was 6.0M (95% CI 5.9 to 6.0). Patients had a median age of 67.5 years (IQR 57.2–78.2, range 0–90); 44.8% were female and 70.0% were non-Hispanic white. The mean weighted annual number of incident infections was 6.2M (95% CI 6.1 to 6.3). Patients had a median age of 63.7 years (IQR 52.8–79.8, range 0–90); 51.3% were female and 68.6% were non-Hispanic white. The number of incident cancer cases in 2014 was 1.5M. Patients had a median age of just over 65 years (<20, 0.9%; 20–49, 11.8%; 50–64, 33.2%; 65–74, 28.5%; ≥75, 25.0%); 50.7% were female and 80.0% were non-Hispanic white. The estimated total annual incidence of all ‘Big Three’ diseases was 13.7M (43.5% vascular events, 45.2% infections, 11.3% cancers) (table 1).

Overall incidence of diagnostic errors and serious harms
Table 1 shows annual estimated disease incidence, diagnostic errors, and serious misdiagnosis related harms by disease and by category (and denotes whether uncertainty for each parameter is represented by CI, PR, or PPR). Serious misdiagnosis-related harms are summarized in Figures 1 and 2. Across the ‘Big Three’ categories, there were 1.51M (PPR 1.12–1.89) missed diagnoses and 603,000 (PPR 454,000–776,000) serious harms; mean diagnostic error and serious harm rates per true disease case for any ‘Big Three’ disease (including ‘other’ subcategories) were 11.1% and 4.4%, respectively. The 15 individually analyzed ‘Big Three’ diseases together accounted for 403,000 serious harms (50.7% of the grand total); mean diagnostic error and serious harm rates per true disease case for the 15 specific diseases (excluding ‘other’ subcategories of the ‘Big Three’) were 11.1% and 6.1%, respectively. Among these, five conditions linked to the largest numbers of serious harms (stroke, sepsis, pneumonia, venous thromboembolism, and lung cancer) together accounted for 308,000 serious harms (38.7% of the grand total). Across all dangerous diseases (including non ‘Big Three’), the grand total estimate was 2.59M (PPR 1.92–3.23) missed diagnoses and 795,000 (PPR 598,000–1,023,000) serious harms (broken down as 371,000 total deaths and 424,000 total disabilities).

Sensitivity analyses and validity checks
The population-level serious harm totals were most sensitive to harm rates for the highest-incidence infections (‘other’ infections, sepsis, pneumonia) and stroke, but even if each of these harm rates were placed at the lower plausible bound of harms for that specific disease, the grand total of serious harms across all diseases would still be over 500,000 (online supplemental file 1-B1). Using only principal diagnosis NIS codes, which assumes a lower disease incidence and reduces any residual risks of double counting, gave lower estimates by about 30% (grand totals 1.78M missed diagnoses and 549,000 serious harms (online
supplemental file 1-B2)). The impact of methodological assumptions on undercounting (online supplemental file 1-B3) and overcounting (online supplemental file 1-B4) were both estimated at <8% and likely offsetting.

Validity checks assessed current results based on similarity to (or coherence with) values derived independently using setting-specific (eg, hospital-based) medical literature. Estimated misdiagnosis-attributable death rates were 14.1% (n = 371 000 of 2.6 M US deaths in 2014) for the primary analysis and 9.8% (n = 256 000 of 2.6 M US deaths in 2014) for the principal-only analysis (online supplemental file 1-C1). By comparison, the literature-derived rate of misdiagnosis-attributable deaths based on hospital autopsies (8.4%, 95% CI...
5.2 to 13.1) and inpatient diagnostic adverse events (~7.4%) were lower, as expected (online supplemental file 1-C1,C2). Our disease-based estimate of total serious misdiagnosis-related harms (across clinical settings) of ~795 000 (PPR 598 000–1 023 000) was comparable to independent literature-derived values using a setting-based (rather than disease-based) approach, which assessed ~855 000 (490 000–1 659 000) serious misdiagnosis-related harms (online supplemental file 1-C3). Estimates of inpatient misdiagnosis-related deaths derived from our disease-based approach (~105 000) fall within the uncertainty bounds of those derived independently from previously published medical literature on hospital autopsies (~82 000 (51 000–128 000)) and hospital-based adverse events.
DiscusSion

This manuscript provides the first robust, national annual US estimate for serious misdiagnosis-related harms (nearly 800,000 combined deaths (~371,000) or permanent disabilities (~424,000)) across care settings (ambulatory clinic, emergency department and inpatient). Even with the most conservative assumptions about disease incidence or disease-specific harms, we estimated the number affected to be over 500,000. The number of affected patients is large, and this makes diagnostic error a pressing public health concern. Our results also suggest that meaningful progress could be made by addressing just a few dangerous diseases that are relatively common—reducing diagnostic errors by ~50% for the 15 named dangerous diseases could potentially prevent ~200,000 serious misdiagnosis-related harms while reducing diagnostic errors by ~50% for the five most harmful diseases (stroke, sepsis, pneumonia, venous thromboembolism and lung cancer) could prevent ~150,000.

Sensitivity analyses and validity checks show serious misdiagnosis-related harm results are robust. The impact of methods-induced undercounting and overcounting were relatively small and likely cancel one another. The credibility of our current estimate is bolstered by convergent construct validity with two alternative methods of estimation using the rate of misdiagnosis-attributable deaths based on hospital autopsies and inpatient diagnostic adverse events. Care setting-based estimates using independent, disease-specific data from two large systematic reviews (inpatient1 and emergency department1) also corroborate our findings.

Our results suggest that diagnostic error is probably the single largest source of deaths across all care settings (~371,000) linked to medical error. This number may exceed estimated deaths from all other patient safety concerns combined, regardless of which prior estimate of total deaths due to medical error (range 12,500–250,00026) is considered. This seems plausible because prior estimates systematically undercount diagnostic errors and diagnostic errors more often cause serious harms than other errors.27

How many misdiagnosis-associated disabilities or deaths are preventable and how much (or little) longevity might potentially be reclaimed for affected patients is uncertain. Preventability is inconsistently judged by different raters, and some remain sceptical that error prevention can meaningfully increase longevity with a good quality of life.28 Nevertheless, there are numerous anecdotes of otherwise healthy young patients in whom a half-century or more of quality life years are likely to have been saved through prompt diagnosis.29 For some of the most harmful diseases in our list, correct initial diagnosis has been associated with substantial reductions in morbidity or mortality (eg, ischaemic stroke (~fivetofold),3 aneurysmal subarachnoid haemorrhage (~fivetofold),30 ruptured abdominal aortic aneurysm (~twofold)).31 Finally, large variation in diagnostic error and harm rates across demographic groups, diseases, clinical settings and individual institutions point to strong prospects of preventability for at least some harms.3 32

Although the study estimated total diagnostic errors (2.59 M), this reflects only errors in patients with dangerous diseases, not all diagnostic errors. Total annual diagnostic errors in the USA likely number in the tens of millions, but the total is likely highly contingent on the threshold for defining a diagnostic error.8 This is different, however, than serious harms (death and permanent disability), which are more objectively defined, so less subject to this particular type of methodological heterogeneity.8

The large absolute numbers of patients harmed should not be mistaken for an inordinately high per-incident case or per-visit risk. According to these results, a patient with a life-threatening or limb-threatening disease has a ~11% chance of being missed; because of the substantial risk of harm when a dangerous disease is missed, that same patient also has a ~4% overall chance of dying or becoming permanently disabled pursuant to a misdiagnosis. Admittedly, both are higher than what medical experts generally think of as an ‘acceptable’ miss rate for dangerous diseases (eg, <0.5%–1%).33–35 However, given over 1 billion healthcare visits per year in the USA,3 a patient visiting a doctor for any reason (ie, who may or may not have a dangerous underlying disease) likely has a <0.1% chance of suffering serious misdiagnosis-related harms. Thus, patients should not panic or lose faith in the healthcare system.

Although the present study focused on US-based estimates, some of our disease-specific error rates were based on data from other high-income countries outside the USA33 and there is good reason to believe that diagnostic errors and misdiagnosis-related harms represent a global problem. There is meta-analytic evidence that hospital-based diagnostic error and harm rates are comparable across North America and Europe, but higher in other countries that were studied.1 Measured error and harm rates in primary care4 6 36 and emergency departments4 are similar in the USA, the UK and Western Europe. In 2015, Organisation for Economic Co-operation and Development (OECD) nations averaged 6.5 doctor consultations per person year37 and had ~1.3 billion persons38—if per-visit serious harm rates are comparable to the USA, this would translate to roughly 7 M serious misdiagnosis-related harms in OECD nations (including the USA). Less
is known about the scope and nature of diagnostic errors in low-income and middle-income nations. However, access to basic diagnostic testing resources are very limited in many low-income and middle-income countries, and diagnostic delays for life-threatening diseases can be substantial, so the global burden for ~7.9 billion persons is likely several-fold higher.

Disease distributions for serious misdiagnosis-related harms differ across clinical settings and age groups. Missed vascular events and infections dominate in hospitals and emergency departments, while missed cancers likely dominate in primary care. In adult care, vascular events are typical, while in paediatric care, infections are typical. Thus, diseases that should be the focus of interventions to improve diagnostic performance would ideally be tailored to the specific clinical context.

This study focused on missed diagnoses (false negatives) of dangerous diseases. While it is desirable to prevent false negatives, practical realities may constrain our ability to do so. Implications for improving diagnosis must consider these results in the broader diagnostic context which includes overuse of diagnostic tests, false positive (mis-)diagnoses, incidental findings and overdiagnosis, because these are also associated with substantial harms and increased healthcare costs. Reducing missed diagnoses by increasing sensitivity at the expense of specificity (ie, trading false negatives for false positives by shifting clinical decision thresholds around ordering tests or interpreting test results) should not be considered ‘improving diagnosis’. Instead, diagnostic innovations that increase both sensitivity and specificity at a given test threshold are needed, as recently shown in a pilot tele-consult programme for dizziness and stroke in the emergency department. Economic modelling may be an important means to estimate the full future impact of solutions designed to improve diagnosis, before they are implemented.

**Limitations**

Our approach relies on literature-derived estimates being roughly representative of US national diagnostic error and serious harm rates, which cannot be directly verified. Although some estimates based on older studies might not generalise to current practice, limited available evidence suggests diagnostic errors are either stable or rising over time in the USA. Population-based incidence estimates for vascular events and infections using the NIS are based on administrative codes that could not be independently clinically verified by our team, but annual disease-specific incidence values were deemed face valid by relevant specialists. Our approach is limited by drawing together data from several sources, each with its own uncertainty, so our final estimates are necessarily less precise than would be desirable. This estimate does not account for the sometimes profound effects of non-disabling suffering due to diagnostic delays of non-lethal illnesses, including prolonged diagnostic odysseys, chronic side effects and risks of treatments administered for diseases patients do not actually have (false positives) and the substantial health effects and economic consequences of overtesting and overdiagnosis. Nevertheless, our national extrapolations are based on current best evidence regarding error/harm rates, triangulate well with data from other sources and are face valid to disease-specific domain experts.

**CONCLUSIONS**

Across clinical settings (ambulatory clinics, emergency department and inpatient), we estimate that nearly 800 000 Americans die or are permanently disabled by diagnostic error each year, making it the single largest source of serious harms from medical mistakes. We believe this is the best estimate currently possible, and, in an area of patient safety where estimates vary widely, results presented here offer an important scientific advance for the field. Although not all these harms are necessarily preventable, our findings add urgency to what the US National Academy of Medicine has already labelled a ‘moral, professional, and public health imperative’. Policymakers have recently taken notice, but diagnostic error-related research still remains substantially underfunded relative to its public health impact—to make progress, this must change. Research and quality improvement programmes should include a strong focus on prompt diagnosis of vascular events, infections and cancers, with an emphasis on the top 15 dangerous diseases identified in this study, which together likely account for half of all serious misdiagnosis-related harms. Prospective, interventional studies are needed to confirm the real-world preventability of these harms.

**Author affiliations**

1 Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
2 Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA
3 Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
4 Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
5 Department of Patient Safety, The Risk Management Foundation of the Harvard Medical Institutions Inc, Boston, Massachusetts, USA
6 Department of Biostatistics, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA
7 Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
8 Candello, The Risk Management Foundation of the Harvard Medical Institutions Inc, Boston, Massachusetts, USA
9 Department of Risk Management & Analytics, Coverys, Boston, Massachusetts, USA
10 Department of Risk Management & Analytics, Covency, Boston, Massachusetts, USA

**Correction notice** This article has been corrected since it was first published online. The following section has been removed from the funding statement: (EPC VI (TOPIC ID 503-4262).)

**Twitter** David E Newman-Toker @DNewmanToker

**Contributors** DEN-T (guarantor): I accept full responsibility for the finished work and the conduct of the study, had access to the data, and controlled the decision to publish. I declare that I designed the study; had primary oversight over the data analysis; designed the figures; authored the primary
manuscript draft and all major revisions and that I have seen and approved the final version. I served as an unpaid member of the Board of Directors of the Society to Improve Diagnosis in Medicine, and as its President (2018–2020). I serve as a legal consultant for both plaintiff and defence in cases related to diagnostic error. I have no other relevant conflicts of interest. NN: I declare that I assisted in study design and conduct; edited the manuscript for scientific content and that I have seen and approved the final version. I have no conflicts of interest. ACS: I declare that I assisted in study design and conduct; edited the manuscript for scientific content and that I have seen and approved the final version. I have no conflicts of interest. NN: I declare that I assisted in study design and conduct; edited the manuscript for scientific content and that I have seen and approved the final version. I have no conflicts of interest. MF: I declare that I assisted in study conduct; edited the manuscript for scientific content and that I have seen and approved the final version. I have no conflicts of interest. AH: I declare that I assisted in study conduct; edited the manuscript for scientific content and that I have seen and approved the final version. I have no conflicts of interest. DS: I declare that I assisted in study design and conduct; edited the manuscript for scientific content and that I have seen and approved the final version. I previously served as an unpaid member of the Board of Directors of the Society to Improve Diagnosis in Medicine.

Funding This study was funded by Society to Improve Diagnosis in Medicine, Agency for Healthcare Research and Quality (R01 HS 27614, R18 HS 029350) and Armstrong Institute for Diagnostic Excellence at the Johns Hopkins University School of Medicine.

Competing interests DEN-T has a career focus and conducts research related to diagnostic errors, including in patients with dizziness and stroke. He serves as the principal investigator for multiple grants and contracts on these topics. DEN-T is an inventor on a provisional patent (US PCT/US2020/070304) for smartphone-based stroke diagnosis in patients with dizziness. He gives frequent academic lectures on these topics and occasionally serves as a medical-legal consultant for both plaintiff and defence in cases related to dizziness, stroke and diagnostic error. DS is also a former volunteer President and member of the Board of Directors of the Society to Improve Diagnosis in Medicine. Johns Hopkins has been loaned research equipment (video-oculography (VOG) systems) by two companies for use in DEN-T’s research; one of these companies has also provided funding for DEN-T’s research on diagnostic algorithms for the development related to dizziness, inner ear diseases and stroke. DEN-T has no other financial interest in these or any other companies. DEN-T is an inventor on a provisional patent (US PCT/US2020/070304) for smartphone-based stroke diagnosis in patients with dizziness. He gives frequent academic lectures on these topics and occasionally serves as a medical-legal consultant for both plaintiff and defence in cases related to dizziness, stroke and diagnostic error. DS is also a former volunteer member of the Board of Directors of the Society to Improve Diagnosis in Medicine. Johns Hopkins has been loaned research equipment (video-oculography (VOG) systems) by two companies for use in DEN-T’s research; one of these companies has also provided funding for DEN-T’s research on diagnostic algorithms for the development related to dizziness, inner ear diseases and stroke. DEN-T has no other financial interest in these or any other companies. DEN-T is an inventor on a provisional patent (US PCT/US2020/070304) for smartphone-based stroke diagnosis in patients with dizziness. He gives frequent academic lectures on these topics and occasionally serves as a medical-legal consultant for both plaintiff and defence in cases related to dizziness, stroke and diagnostic error. DS is also a former volunteer member of the Board of Directors of the Society to Improve Diagnosis in Medicine. There are no other conflicts of interest. None of the authors have any financial or personal relationships with other people or organisations that could inappropriately influence (bias) their work.

Patient consent for publication Not applicable.

Ethics approval No human subjects participated in this study, and no institutional review board approval was needed.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available in a public, open access repository. Data on disease incidence used for the study are all publicly available; these public-use datasets and accompanying standard data dictionaries may be found at the URL locations cited in the references list. Additional details regarding sources and methods for diagnostic error and harm rate calculations may be found in three prior publications (PMID: 31533832, 32412440, 36574284), including their associated appendices and online supplemental materials.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

ORCID iD David E. Newman-Toker http://orcid.org/0000-0003-2789-4115

REFERENCES


40 Chimaturi GL, Rhoda AJ. Scoping review of acute stroke care management and rehabilitation in low and middle-income countries. BMC Health Serv Res 2019;19:789.
46 Ong MS, Mandl KD. National expenditure for false-positive mammograms and breast cancer overdiaognoses estimated at $4 billion a year. Health Aff (Millwood) 2015;34:576–83.
47 Newman-Toker DE, McDonald KM, Meltzer DO. How much diagnostic safety can we afford, and how should we...


